Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803867 · ClinicalTrials.gov registry record · Phase 1
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 17
- Study locations
NCT01803867 is a Phase 1 study of Multiple Sclerosis that has completed, run by Acorda Therapeutics. The registered enrollment target is 72 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT01803867, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.
Conditions Studied
Interventions
- DRUG rHIgM22
Study Locations (17)
California
- Acorda Investigational Site - Long Beach
- Acorda Investigational Site - Palo Alto
- Acorda Investigational Site - Sacramento
- Acorda Investigational Site - Stanford
Colorado
- Acorda Investigational Site - Aurora
- Acorda Investigational Site - Centennial
Washington
- Acorda Investigational Site - Seattle
- Acorda Investigational Site - Seattle
Indiana
- Acorda Investigational Site - Indianapolis
Kansas
- Acorda Investigational Site - Kansas City
Maryland
- Acorda Investigational Site - Baltimore
Missouri
- Acorda Investigational Site - St Louis
New York
- Acorda Investigational Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01803867
The ClinicalTrials.gov registry entry for NCT01803867 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (88% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which rHIgM22 is the first listed.
NCT01803867 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT01803867 about?
NCT01803867 is a clinical study titled "An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis". This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.
What is the current status of trial NCT01803867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-03. Estimated completion is 2015-01.
What conditions does trial NCT01803867 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01803867?
The interventions under investigation include: rHIgM22 (DRUG).
Who is sponsoring clinical trial NCT01803867?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01803867 being conducted?
This trial has 17 study locations across California, Colorado, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.